Hepatitis B - Pipeline Review, H2 2016
ReportsWeb.com has announced the addition of the “Hepatitis B - Pipeline Review, H2 2016” this report provides an overview of the Hepatitis B (Infectious Disease) pipeline landscape.
(EMAILWIRE.COM, June 22, 2017 ) Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus. Hepatitis B virus can cause an acute illness with symptoms that last several weeks, including yellowing of the skin and eyes (jaundice), dark urine, extreme fatigue, nausea, vomiting and abdominal pain. Risk factors include age, severe kidney disease, hemophilia, share needles during drug use and born to a hepatitis-b infected mother. Treatment includes antiviral drugs.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Hepatitis B - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hepatitis B (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hepatitis B (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis B and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 3, 10, 24, 18, 3, 58, 33 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 3, 7 and 6 molecules, respectively.Hepatitis B.
Hepatitis B (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/hepatitis-b-pipeline-review-h2-2016
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis B (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Hepatitis B (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hepatitis B (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hepatitis B (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis B (Infectious Disease)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001499732/sample
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hepatitis B (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hepatitis B (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles
Abivax SA
AiCuris GmbH & Co KG
AIMM Therapeutics BV
Akshaya Bio Inc
Alnylam Pharmaceuticals Inc
AlphaMab Co., Ltd
Altimmune Inc
Altravax Inc
Amarna Therapeutics BV
Arbutus Biopharma Corp
Arcturus Therapeutics Inc
Arrowhead Pharmaceuticals Inc
Assembly Biosciences Inc
Beijing Kawin Technology Share-Holding Co Ltd
Beijing Minhai Biotechnology Co Ltd
Benitec Biopharma Ltd
Biogenomics Limited
Biological E Ltd
BioStar Pharmaceuticals Inc
Bolder Biotechnology Inc
BrightGene Bio-Medical Technology Co Ltd
Bukwang PharmCo Ltd
CaroGen Corp
Celltrion Inc
Chong Kun Dang Pharmaceutical Corp
Chromis Therapeutics, Inc.
ChronTech Pharma AB
Cocrystal Pharma Inc
ContraVir Pharmaceuticals Inc
CyTuVax BV
Dicerna Pharmaceuticals Inc
Dong-A Socio Holdings Co Ltd
Dynavax Technologies Corp
Ensemble Therapeutics Corp
eTheRNA Immunotherapies NV
F. Hoffmann-La Roche Ltd
GeneCure LLC
GeoVax Labs Inc
Gilead Sciences Inc
GlaxoSmithKline Plc
Green Cross Corp
Hanmi Pharmaceuticals Co Ltd
HEC Pharm Co., Ltd.
Humabs BioMed SA
Huons Co Ltd
Ildong Pharmaceutical Co Ltd
Immunotope Inc
Indian Immunologicals Ltd
Intellia Therapeutics Inc
Ionis Pharmaceuticals Inc
ISA Pharmaceuticals BV
Jiangsu Hansoh Pharmaceutical Co Ltd
Johnson & Johnson
Kineta Inc
Lakewood-Amedex Inc
Leukocare AG
LG Life Science LTD
Ligand Pharmaceuticals Inc
Mucosis BV
MultiCell Technologies Inc
Oncolys BioPharma Inc
Panacea Biotec Ltd
Pfenex Inc
PharmaEssentia Corp
Poxel SA
Profarma
Profectus BioSciences Inc
Redx Pharma Plc
REPLICor Inc
Rodos BioTarget GmbH
Samjin Pharmaceutical Co Ltd
Sanofi Pasteur SA
Shantha Biotechnics Ltd
Sinovac Biotech Ltd
Spring Bank Pharmaceuticals Inc
Staidson (Beijing) Biopharmaceuticals Co., Ltd.
TCM Biotech International Corp
TetraLogic Pharmaceuticals
TGV-Laboratories
Theravectys SA
Tomegavax Inc
Transgene SA
Vaxine Pty Ltd
VBI Vaccines Inc
Viriom Ltd
VLP Biotech Inc
Zydus Cadila Healthcare Ltd
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001499732/discount
List of Tables
Number of Products under Development for Hepatitis B, H2 2016 27
Number of Products under Development for Hepatitis B - Comparative Analysis, H2 2016 28
Number of Products under Development by Companies, H2 2016 30
Number of Products under Development by Companies, H2 2016 (Contd..1) 31
Number of Products under Development by Companies, H2 2016 (Contd..2) 32
Number of Products under Development by Companies, H2 2016 (Contd..3) 33
Number of Products under Development by Companies, H2 2016 (Contd..4) 34
Number of Products under Development by Companies, H2 2016 (Contd..5) 35
Number of Products under Development by Companies, H2 2016 (Contd..6) 36
Number of Products under Investigation by Universities/Institutes, H2 2016 37
Comparative Analysis by Late Stage Development, H2 2016 38
Comparative Analysis by Clinical Stage Development, H2 2016 39
Comparative Analysis by Early Stage Development, H2 2016 40
Comparative Analysis by Unknown Stage Development, H2 2016 41
Products under Development by Companies, H2 2016 42
Products under Development by Companies, H2 2016 (Contd..1) 43
Products under Development by Companies, H2 2016 (Contd..2) 44
Products under Development by Companies, H2 2016 (Contd..3) 45
Products under Development by Companies, H2 2016 (Contd..4) 46
Products under Development by Companies, H2 2016 (Contd..5) 47
Products under Development by Companies, H2 2016 (Contd..6) 48
Products under Development by Companies, H2 2016 (Contd..7) 49
Products under Development by Companies, H2 2016 (Contd..8) 50
Products under Investigation by Universities/Institutes, H2 2016 51
Hepatitis B - Pipeline by Abivax SA, H2 2016 52
Hepatitis B - Pipeline by AiCuris GmbH & Co KG, H2 2016 53
Hepatitis B - Pipeline by AIMM Therapeutics BV, H2 2016 54
Hepatitis B - Pipeline by Akshaya Bio Inc, H2 2016 55
Hepatitis B - Pipeline by Alnylam Pharmaceuticals Inc, H2 2016 56
Hepatitis B - Pipeline by AlphaMab Co., Ltd, H2 2016 57
Hepatitis B - Pipeline by Altimmune Inc, H2 2016 58
Hepatitis B - Pipeline by Altravax Inc, H2 2016 59
Hepatitis B - Pipeline by Amarna Therapeutics BV, H2 2016 60
Hepatitis B - Pipeline by Arbutus Biopharma Corp, H2 2016 61
Hepatitis B - Pipeline by Arcturus Therapeutics Inc, H2 2016 62
Hepatitis B - Pipeline by Arrowhead Pharmaceuticals Inc, H2 2016 63
Hepatitis B - Pipeline by Assembly Biosciences Inc, H2 2016 64
Hepatitis B - Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, H2 2016 65
Hepatitis B - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2016 66
Hepatitis B - Pipeline by Benitec Biopharma Ltd, H2 2016 67
Hepatitis B - Pipeline by Biogenomics Limited, H2 2016 68
Hepatitis B - Pipeline by Biological E Ltd, H2 2016 69
Hepatitis B - Pipeline by BioStar Pharmaceuticals Inc, H2 2016 70
Hepatitis B - Pipeline by Bolder Biotechnology Inc, H2 2016 71
Hepatitis B - Pipeline by BrightGene Bio-Medical Technology Co Ltd, H2 2016 72
Hepatitis B - Pipeline by Bukwang PharmCo Ltd, H2 2016 73
Hepatitis B - Pipeline by CaroGen Corp, H2 2016 74
Hepatitis B - Pipeline by Celltrion Inc, H2 2016 75
Hepatitis B - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2016 76
Hepatitis B - Pipeline by Chromis Therapeutics, Inc., H2 2016 77
Hepatitis B - Pipeline by ChronTech Pharma AB, H2 2016 78
Hepatitis B - Pipeline by Cocrystal Pharma Inc, H2 2016 79
Hepatitis B - Pipeline by ContraVir Pharmaceuticals Inc, H2 2016 80
Hepatitis B - Pipeline by CyTuVax BV, H2 2016 81
Hepatitis B - Pipeline by Dicerna Pharmaceuticals Inc, H2 2016 82
Hepatitis B - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2016 83
Hepatitis B - Pipeline by Dynavax Technologies Corp, H2 2016 84
Hepatitis B - Pipeline by Ensemble Therapeutics Corp, H2 2016 85
Hepatitis B - Pipeline by eTheRNA Immunotherapies NV, H2 2016 86
Hepatitis B - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 87
Hepatitis B - Pipeline by GeneCure LLC, H2 2016 88
Hepatitis B - Pipeline by GeoVax Labs Inc, H2 2016 89
Hepatitis B - Pipeline by Gilead Sciences Inc, H2 2016 90
Hepatitis B - Pipeline by GlaxoSmithKline Plc, H2 2016 91
Hepatitis B - Pipeline by Green Cross Corp, H2 2016 92
Hepatitis B - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016 93
Hepatitis B - Pipeline by HEC Pharm Co., Ltd., H2 2016 94
Hepatitis B - Pipeline by Humabs BioMed SA, H2 2016 95
Hepatitis B - Pipeline by Huons Co Ltd, H2 2016 96
Hepatitis B - Pipeline by Ildong Pharmaceutical Co Ltd, H2 2016 97
Hepatitis B - Pipeline by Immunotope Inc, H2 2016 98
Hepatitis B - Pipeline by Indian Immunologicals Ltd, H2 2016 99
Hepatitis B - Pipeline by Intellia Therapeutics Inc, H2 2016 100
Hepatitis B - Pipeline by Ionis Pharmaceuticals Inc, H2 2016 101
Hepatitis B - Pipeline by ISA Pharmaceuticals BV, H2 2016 102
Hepatitis B - Pipeline by Jiangsu Hansoh Pharmaceutical Co Ltd, H2 2016 103
Hepatitis B - Pipeline by Johnson & Johnson, H2 2016 104
Hepatitis B - Pipeline by Kineta Inc, H2 2016 105
Hepatitis B - Pipeline by Lakewood-Amedex Inc, H2 2016 106
Hepatitis B - Pipeline by Leukocare AG, H2 2016 107
Hepatitis B - Pipeline by LG Life Science LTD, H2 2016 108
Hepatitis B - Pipeline by Ligand Pharmaceuticals Inc, H2 2016 109
Hepatitis B - Pipeline by Mucosis BV, H2 2016 110
Hepatitis B - Pipeline by MultiCell Technologies Inc, H2 2016 111
Hepatitis B - Pipeline by Oncolys BioPharma Inc, H2 2016 112
Hepatitis B - Pipeline by Panacea Biotec Ltd, H2 2016 113
Hepatitis B - Pipeline by Pfenex Inc, H2 2016 114
Hepatitis B - Pipeline by PharmaEssentia Corp, H2 2016 115
Hepatitis B - Pipeline by Poxel SA, H2 2016 116
Hepatitis B - Pipeline by Profarma, H2 2016 117
Hepatitis B - Pipeline by Profectus BioSciences Inc, H2 2016 118
Hepatitis B - Pipeline by Redx Pharma Plc, H2 2016 119
Hepatitis B - Pipeline by REPLICor Inc, H2 2016 120
Hepatitis B - Pipeline by Rodos BioTarget GmbH, H2 2016 121
Hepatitis B - Pipeline by Samjin Pharmaceutical Co Ltd, H2 2016 122
Hepatitis B - Pipeline by Sanofi Pasteur SA, H2 2016 123
Hepatitis B - Pipeline by Shantha Biotechnics Ltd, H2 2016 124
Hepatitis B - Pipeline by Sinovac Biotech Ltd, H2 2016 125
Hepatitis B - Pipeline by Spring Bank Pharmaceuticals Inc, H2 2016 126
Hepatitis B - Pipeline by Staidson (Beijing) Biopharmaceuticals Co., Ltd., H2 2016 127
Hepatitis B - Pipeline by TCM Biotech International Corp, H2 2016 128
Hepatitis B - Pipeline by TetraLogic Pharmaceuticals, H2 2016 129
Hepatitis B - Pipeline by TGV-Laboratories, H2 2016 130
Hepatitis B - Pipeline by Theravectys SA, H2 2016 131
Hepatitis B - Pipeline by Tomegavax Inc, H2 2016 132
Hepatitis B - Pipeline by Transgene SA, H2 2016 133
Hepatitis B - Pipeline by Vaxine Pty Ltd, H2 2016 134
Hepatitis B - Pipeline by VBI Vaccines Inc, H2 2016 135
Hepatitis B - Pipeline by Viriom Ltd, H2 2016 136
Hepatitis B - Pipeline by VLP Biotech Inc, H2 2016 137
Hepatitis B - Pipeline by Zydus Cadila Healthcare Ltd, H2 2016 138
Assessment by Monotherapy Products, H2 2016 139
Assessment by Combination Products, H2 2016 140
Number of Products by Stage and Target, H2 2016 142
Number of Products by Stage and Mechanism of Action, H2 2016 145
Number of Products by Stage and Route of Administration, H2 2016 148
Number of Products by Stage and Molecule Type, H2 2016 150
Hepatitis B - Dormant Projects, H2 2016 363
Hepatitis B - Dormant Projects (Contd..1), H2 2016 364
Hepatitis B - Dormant Projects (Contd..2), H2 2016 365
Hepatitis B - Dormant Projects (Contd..3), H2 2016 366
Hepatitis B - Dormant Projects (Contd..4), H2 2016 367
Hepatitis B - Dormant Projects (Contd..5), H2 2016 368
Hepatitis B - Dormant Projects (Contd..6), H2 2016 369
Hepatitis B - Dormant Projects (Contd..7), H2 2016 370
Hepatitis B - Dormant Projects (Contd..8), H2 2016 371
Hepatitis B - Dormant Projects (Contd..9), H2 2016 372
Hepatitis B - Dormant Projects (Contd..10), H2 2016 373
Hepatitis B - Dormant Projects (Contd..11), H2 2016 374
Hepatitis B - Discontinued Products, H2 2016 375
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001499732/buy/2000
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Hepatitis B - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hepatitis B (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hepatitis B (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis B and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 3, 10, 24, 18, 3, 58, 33 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 3, 7 and 6 molecules, respectively.Hepatitis B.
Hepatitis B (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/hepatitis-b-pipeline-review-h2-2016
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis B (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Hepatitis B (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hepatitis B (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hepatitis B (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis B (Infectious Disease)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001499732/sample
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hepatitis B (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hepatitis B (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles
Abivax SA
AiCuris GmbH & Co KG
AIMM Therapeutics BV
Akshaya Bio Inc
Alnylam Pharmaceuticals Inc
AlphaMab Co., Ltd
Altimmune Inc
Altravax Inc
Amarna Therapeutics BV
Arbutus Biopharma Corp
Arcturus Therapeutics Inc
Arrowhead Pharmaceuticals Inc
Assembly Biosciences Inc
Beijing Kawin Technology Share-Holding Co Ltd
Beijing Minhai Biotechnology Co Ltd
Benitec Biopharma Ltd
Biogenomics Limited
Biological E Ltd
BioStar Pharmaceuticals Inc
Bolder Biotechnology Inc
BrightGene Bio-Medical Technology Co Ltd
Bukwang PharmCo Ltd
CaroGen Corp
Celltrion Inc
Chong Kun Dang Pharmaceutical Corp
Chromis Therapeutics, Inc.
ChronTech Pharma AB
Cocrystal Pharma Inc
ContraVir Pharmaceuticals Inc
CyTuVax BV
Dicerna Pharmaceuticals Inc
Dong-A Socio Holdings Co Ltd
Dynavax Technologies Corp
Ensemble Therapeutics Corp
eTheRNA Immunotherapies NV
F. Hoffmann-La Roche Ltd
GeneCure LLC
GeoVax Labs Inc
Gilead Sciences Inc
GlaxoSmithKline Plc
Green Cross Corp
Hanmi Pharmaceuticals Co Ltd
HEC Pharm Co., Ltd.
Humabs BioMed SA
Huons Co Ltd
Ildong Pharmaceutical Co Ltd
Immunotope Inc
Indian Immunologicals Ltd
Intellia Therapeutics Inc
Ionis Pharmaceuticals Inc
ISA Pharmaceuticals BV
Jiangsu Hansoh Pharmaceutical Co Ltd
Johnson & Johnson
Kineta Inc
Lakewood-Amedex Inc
Leukocare AG
LG Life Science LTD
Ligand Pharmaceuticals Inc
Mucosis BV
MultiCell Technologies Inc
Oncolys BioPharma Inc
Panacea Biotec Ltd
Pfenex Inc
PharmaEssentia Corp
Poxel SA
Profarma
Profectus BioSciences Inc
Redx Pharma Plc
REPLICor Inc
Rodos BioTarget GmbH
Samjin Pharmaceutical Co Ltd
Sanofi Pasteur SA
Shantha Biotechnics Ltd
Sinovac Biotech Ltd
Spring Bank Pharmaceuticals Inc
Staidson (Beijing) Biopharmaceuticals Co., Ltd.
TCM Biotech International Corp
TetraLogic Pharmaceuticals
TGV-Laboratories
Theravectys SA
Tomegavax Inc
Transgene SA
Vaxine Pty Ltd
VBI Vaccines Inc
Viriom Ltd
VLP Biotech Inc
Zydus Cadila Healthcare Ltd
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001499732/discount
List of Tables
Number of Products under Development for Hepatitis B, H2 2016 27
Number of Products under Development for Hepatitis B - Comparative Analysis, H2 2016 28
Number of Products under Development by Companies, H2 2016 30
Number of Products under Development by Companies, H2 2016 (Contd..1) 31
Number of Products under Development by Companies, H2 2016 (Contd..2) 32
Number of Products under Development by Companies, H2 2016 (Contd..3) 33
Number of Products under Development by Companies, H2 2016 (Contd..4) 34
Number of Products under Development by Companies, H2 2016 (Contd..5) 35
Number of Products under Development by Companies, H2 2016 (Contd..6) 36
Number of Products under Investigation by Universities/Institutes, H2 2016 37
Comparative Analysis by Late Stage Development, H2 2016 38
Comparative Analysis by Clinical Stage Development, H2 2016 39
Comparative Analysis by Early Stage Development, H2 2016 40
Comparative Analysis by Unknown Stage Development, H2 2016 41
Products under Development by Companies, H2 2016 42
Products under Development by Companies, H2 2016 (Contd..1) 43
Products under Development by Companies, H2 2016 (Contd..2) 44
Products under Development by Companies, H2 2016 (Contd..3) 45
Products under Development by Companies, H2 2016 (Contd..4) 46
Products under Development by Companies, H2 2016 (Contd..5) 47
Products under Development by Companies, H2 2016 (Contd..6) 48
Products under Development by Companies, H2 2016 (Contd..7) 49
Products under Development by Companies, H2 2016 (Contd..8) 50
Products under Investigation by Universities/Institutes, H2 2016 51
Hepatitis B - Pipeline by Abivax SA, H2 2016 52
Hepatitis B - Pipeline by AiCuris GmbH & Co KG, H2 2016 53
Hepatitis B - Pipeline by AIMM Therapeutics BV, H2 2016 54
Hepatitis B - Pipeline by Akshaya Bio Inc, H2 2016 55
Hepatitis B - Pipeline by Alnylam Pharmaceuticals Inc, H2 2016 56
Hepatitis B - Pipeline by AlphaMab Co., Ltd, H2 2016 57
Hepatitis B - Pipeline by Altimmune Inc, H2 2016 58
Hepatitis B - Pipeline by Altravax Inc, H2 2016 59
Hepatitis B - Pipeline by Amarna Therapeutics BV, H2 2016 60
Hepatitis B - Pipeline by Arbutus Biopharma Corp, H2 2016 61
Hepatitis B - Pipeline by Arcturus Therapeutics Inc, H2 2016 62
Hepatitis B - Pipeline by Arrowhead Pharmaceuticals Inc, H2 2016 63
Hepatitis B - Pipeline by Assembly Biosciences Inc, H2 2016 64
Hepatitis B - Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, H2 2016 65
Hepatitis B - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2016 66
Hepatitis B - Pipeline by Benitec Biopharma Ltd, H2 2016 67
Hepatitis B - Pipeline by Biogenomics Limited, H2 2016 68
Hepatitis B - Pipeline by Biological E Ltd, H2 2016 69
Hepatitis B - Pipeline by BioStar Pharmaceuticals Inc, H2 2016 70
Hepatitis B - Pipeline by Bolder Biotechnology Inc, H2 2016 71
Hepatitis B - Pipeline by BrightGene Bio-Medical Technology Co Ltd, H2 2016 72
Hepatitis B - Pipeline by Bukwang PharmCo Ltd, H2 2016 73
Hepatitis B - Pipeline by CaroGen Corp, H2 2016 74
Hepatitis B - Pipeline by Celltrion Inc, H2 2016 75
Hepatitis B - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2016 76
Hepatitis B - Pipeline by Chromis Therapeutics, Inc., H2 2016 77
Hepatitis B - Pipeline by ChronTech Pharma AB, H2 2016 78
Hepatitis B - Pipeline by Cocrystal Pharma Inc, H2 2016 79
Hepatitis B - Pipeline by ContraVir Pharmaceuticals Inc, H2 2016 80
Hepatitis B - Pipeline by CyTuVax BV, H2 2016 81
Hepatitis B - Pipeline by Dicerna Pharmaceuticals Inc, H2 2016 82
Hepatitis B - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2016 83
Hepatitis B - Pipeline by Dynavax Technologies Corp, H2 2016 84
Hepatitis B - Pipeline by Ensemble Therapeutics Corp, H2 2016 85
Hepatitis B - Pipeline by eTheRNA Immunotherapies NV, H2 2016 86
Hepatitis B - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 87
Hepatitis B - Pipeline by GeneCure LLC, H2 2016 88
Hepatitis B - Pipeline by GeoVax Labs Inc, H2 2016 89
Hepatitis B - Pipeline by Gilead Sciences Inc, H2 2016 90
Hepatitis B - Pipeline by GlaxoSmithKline Plc, H2 2016 91
Hepatitis B - Pipeline by Green Cross Corp, H2 2016 92
Hepatitis B - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016 93
Hepatitis B - Pipeline by HEC Pharm Co., Ltd., H2 2016 94
Hepatitis B - Pipeline by Humabs BioMed SA, H2 2016 95
Hepatitis B - Pipeline by Huons Co Ltd, H2 2016 96
Hepatitis B - Pipeline by Ildong Pharmaceutical Co Ltd, H2 2016 97
Hepatitis B - Pipeline by Immunotope Inc, H2 2016 98
Hepatitis B - Pipeline by Indian Immunologicals Ltd, H2 2016 99
Hepatitis B - Pipeline by Intellia Therapeutics Inc, H2 2016 100
Hepatitis B - Pipeline by Ionis Pharmaceuticals Inc, H2 2016 101
Hepatitis B - Pipeline by ISA Pharmaceuticals BV, H2 2016 102
Hepatitis B - Pipeline by Jiangsu Hansoh Pharmaceutical Co Ltd, H2 2016 103
Hepatitis B - Pipeline by Johnson & Johnson, H2 2016 104
Hepatitis B - Pipeline by Kineta Inc, H2 2016 105
Hepatitis B - Pipeline by Lakewood-Amedex Inc, H2 2016 106
Hepatitis B - Pipeline by Leukocare AG, H2 2016 107
Hepatitis B - Pipeline by LG Life Science LTD, H2 2016 108
Hepatitis B - Pipeline by Ligand Pharmaceuticals Inc, H2 2016 109
Hepatitis B - Pipeline by Mucosis BV, H2 2016 110
Hepatitis B - Pipeline by MultiCell Technologies Inc, H2 2016 111
Hepatitis B - Pipeline by Oncolys BioPharma Inc, H2 2016 112
Hepatitis B - Pipeline by Panacea Biotec Ltd, H2 2016 113
Hepatitis B - Pipeline by Pfenex Inc, H2 2016 114
Hepatitis B - Pipeline by PharmaEssentia Corp, H2 2016 115
Hepatitis B - Pipeline by Poxel SA, H2 2016 116
Hepatitis B - Pipeline by Profarma, H2 2016 117
Hepatitis B - Pipeline by Profectus BioSciences Inc, H2 2016 118
Hepatitis B - Pipeline by Redx Pharma Plc, H2 2016 119
Hepatitis B - Pipeline by REPLICor Inc, H2 2016 120
Hepatitis B - Pipeline by Rodos BioTarget GmbH, H2 2016 121
Hepatitis B - Pipeline by Samjin Pharmaceutical Co Ltd, H2 2016 122
Hepatitis B - Pipeline by Sanofi Pasteur SA, H2 2016 123
Hepatitis B - Pipeline by Shantha Biotechnics Ltd, H2 2016 124
Hepatitis B - Pipeline by Sinovac Biotech Ltd, H2 2016 125
Hepatitis B - Pipeline by Spring Bank Pharmaceuticals Inc, H2 2016 126
Hepatitis B - Pipeline by Staidson (Beijing) Biopharmaceuticals Co., Ltd., H2 2016 127
Hepatitis B - Pipeline by TCM Biotech International Corp, H2 2016 128
Hepatitis B - Pipeline by TetraLogic Pharmaceuticals, H2 2016 129
Hepatitis B - Pipeline by TGV-Laboratories, H2 2016 130
Hepatitis B - Pipeline by Theravectys SA, H2 2016 131
Hepatitis B - Pipeline by Tomegavax Inc, H2 2016 132
Hepatitis B - Pipeline by Transgene SA, H2 2016 133
Hepatitis B - Pipeline by Vaxine Pty Ltd, H2 2016 134
Hepatitis B - Pipeline by VBI Vaccines Inc, H2 2016 135
Hepatitis B - Pipeline by Viriom Ltd, H2 2016 136
Hepatitis B - Pipeline by VLP Biotech Inc, H2 2016 137
Hepatitis B - Pipeline by Zydus Cadila Healthcare Ltd, H2 2016 138
Assessment by Monotherapy Products, H2 2016 139
Assessment by Combination Products, H2 2016 140
Number of Products by Stage and Target, H2 2016 142
Number of Products by Stage and Mechanism of Action, H2 2016 145
Number of Products by Stage and Route of Administration, H2 2016 148
Number of Products by Stage and Molecule Type, H2 2016 150
Hepatitis B - Dormant Projects, H2 2016 363
Hepatitis B - Dormant Projects (Contd..1), H2 2016 364
Hepatitis B - Dormant Projects (Contd..2), H2 2016 365
Hepatitis B - Dormant Projects (Contd..3), H2 2016 366
Hepatitis B - Dormant Projects (Contd..4), H2 2016 367
Hepatitis B - Dormant Projects (Contd..5), H2 2016 368
Hepatitis B - Dormant Projects (Contd..6), H2 2016 369
Hepatitis B - Dormant Projects (Contd..7), H2 2016 370
Hepatitis B - Dormant Projects (Contd..8), H2 2016 371
Hepatitis B - Dormant Projects (Contd..9), H2 2016 372
Hepatitis B - Dormant Projects (Contd..10), H2 2016 373
Hepatitis B - Dormant Projects (Contd..11), H2 2016 374
Hepatitis B - Discontinued Products, H2 2016 375
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001499732/buy/2000
Contact Information:
ReportsWeb.com
Priya Sisodia
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
ReportsWeb.com
Priya Sisodia
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results